Tamaki Yahata

Dr. Tamaki Yahata

Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
TYTamaki Yahata
Tamaki Yahata
MMMika Mizoguchi
Mika Mizoguchi
AKAkihiko Kimura
Akihiko Kimura
TOTakashi Orimo
Takashi Orimo
STSaori Toujima
Saori Toujima
KIKazuhiko Ino
Kazuhiko Ino
Programmed cell death ligand 1 (PD‐L1) on tumor cells suppresses anti‐tumor immunity and has an unfavorable prognostic impact in ovarian cancer patients. We herein report the pathophysiological and therapeutic impacts of PD‐L1 disruption in ovarian cancer. PD‐L1 was genetically disrupted in the murine ovarian cancer cell line ID8 using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9‐mediated genome editing. PD‐L1 knockout (KO) and control ovarian cancer cells were intraperitoneally inoculated into syngeneic mice, and survival and tumor dissemination were evaluated. Survival times were significantly longer in the PD‐L1‐KO ID8‐inoculated groups than in their control groups, and its therapeutic benefit was enhanced in combination with the cisplatin treatment. Tumor weights and ascites volumes were significantly lower in the PD‐L1‐KO ID8 groups than in their control groups. Immunohistochemical and immunofluorescence analyses showed that intratumoral CD4+ T cells, CD8+ T cells, NK cells and CD11c+ M1 macrophages were significantly increased, whereas regulatory T cells were significantly decreased in the PD‐L1‐KO ID8 groups compared with those in their control groups. The intratumoral mRNA expression of interferon‐γ, tumor‐necrosis factor‐α, interleukin (IL)‐2, IL‐12a, CXCL9 and CXCL10 was significantly stronger, while that of IL‐10, vascular endothelial growth factor, CXCL1 and CXCL2 was significantly weaker in the PD‐L1‐KO ID8 groups. These results indicate that CRISPR/Cas9‐mediated PD‐L1 disruption on tumor cells promotes anti‐tumor immunity by increasing tumor‐infiltrating lymphocytes and modulating cytokine/chemokine profiles within the tumor microenvironment, thereby suppressing ovarian cancer progression. These results suggest that PD‐L1‐targeted therapy by genome editing may be a novel therapeutic strategy for ovarian cancer.

1 October 2021 in Gynecology and Minimally Invasive Therapy
Verified
Journal Article
Open access
PDF file
Yasushi KotaniYasushi Kotani
Yasushi Kotani
KMKosuke Murakamsi
Kosuke Murakamsi
SKSayaka Kai
Sayaka Kai
TYTamaki Yahata
Tamaki Yahata
AKAkiko Kanto
Akiko Kanto
NMNoriomi Matsumura
Noriomi Matsumura
Objectives: Pelvic organ prolapse (POP) is relatively high for a gynecologic disease. Laparoscopic sacrocolpopexy (LSC) is currently the main surgical option for managing POP. The priority of the surgical treatment is preventing recurrence after the surgery. We presented the surgical outcome and recurrence rate of LSC and compared the data of LSC with that of other surgical procedures for managing POP to examine the effectiveness of LSC over other them. Materials and Methods: We compared the results of 138 cases of LSC with other conventional procedures, namely 30 cases of total vaginal hysterectomy (TVH) combined with colporrhaphy anterior and posterior, 66 cases of the Manchester operation, and 68 cases of colpocleisis. We compared the age, body mass index, operative time, blood loss volume, postoperative hospital stay duration, rate of complications, recurrence rate, reoperation rate, and the cumulative recurrence rate after 10 years. Results: The complication rate of LSC, TVH, the Manchester operation, and colpocleisis was 2.2%, 3.3%, 3.0%, and 4.4%; the recurrence rate 2.8%, 3.5%, 4.5%, and 8.7%; and the cumulative recurrence rate after 10 years 3.7%, 4.6%, 8.8%, and 18.2%. There was no significant difference between LSC and the other three groups. Conclusion: LSC seems to be an effective surgical option that requires a higher skill level than other surgical methods and has a longer operative time, lesser operative invasion, and a lower long-term recurrence rate. We will actively recommend LSC to those when appropriate.

18 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NINaoyuki Iwahashi
Naoyuki Iwahashi
KSKazuko Sakai
Kazuko Sakai
TNTomoko Noguchi
Tomoko Noguchi
TYTamaki Yahata
Tamaki Yahata
HMHitomi Matsukawa
Hitomi Matsukawa
KIKazuhiko Ino
Kazuhiko Ino
Liquid biopsies of circulating tumor DNA (ctDNA) have recently been used as a non-invasive diagnostic tool for detecting tumor-specific mutations. We present a study of ctDNA liquid biopsies in gynecological cancer using an ultrasensitive next-generation sequencing-based method for ctDNA detection named CAncer Personalized Profiling by deep Sequencing (CAPP-Seq). We performed CAPP-Seq with plasma-ctDNA obtained from 16 patients with gynecological cancer. In all cases, at least one non-synonymous somatic mutation was detected in the ctDNA. In the pre-treatment ctDNA, 4 of 16, 4/16, 5/16, 2/16, 2/16, and 2/16 patients had TP53, KRAS, APC, PIK3CA, BRCA1, and EGFR mutations, respectively. MET gene copy-number gains were detected in the ctDNA of 2 of 16 patients, and FISH analysis of the paired tumor samples confirmed these results. In 2 neoadjuvant chemotherapy-treated ovarian cancer patients, the changes in gene mutation patterns were associated with the treatment response. These findings suggest that CAPP-Seq-based liquid biopsies can be used for the genetic characterization of independent gynecological cancers with high frequency, and might be clinically useful for non-invasive tumor genotyping and therapeutic response monitoring.

20 September 2017 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
SNSakiko Nanjo
Sakiko Nanjo
SMSawako Minami
Sawako Minami
MMMika Mizoguchi
Mika Mizoguchi
MYMadoka Yamamoto
Madoka Yamamoto
TYTamaki Yahata
Tamaki Yahata
KIKazuhiko Ino
Kazuhiko Ino

6 November 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMika Mizoguchi
Mika Mizoguchi
YIYuko Ishida
Yuko Ishida
MNMizuho Nosaka
Mizuho Nosaka
AKAkihiko Kimura
Akihiko Kimura
YKYumi Kuninaka
Yumi Kuninaka
TKToshikazu Kondo
Toshikazu Kondo
Preterm labor (PTL) is the most common cause of neonatal death and long-term adverse outcome. The pharmacological agents for PTL prevention are palliative and frequently fail to prevent PTL and improve neonatal outcome. It is essential to fully understand the molecular mechanisms of PTL in order to develop novel therapeutic methods against PTL. Several lines of evidence indicate some chemokines are expressed in gestational tissues during labor or PTL. To reveal the pathophysiological roles of the CX3CL1-CX3CR1 axis in PTL, we performed present study using LPS-induced PTL mice model in CX3CR1-deficient (Cx3cr1-/-) mice. We indicated that PTL was suppressed in Cx3cr1-/- mice and immunoneutralization of CX3CL1 in WT mice. From immunohistochemical and the gene expression analyses, the CX3CL1-CX3CR1 axis has detrimental roles in PTL through intrauterine recruitment of macrophages and the enhancement of macrophage-derived inflammatory mediators. Thus, the CX3CL1-CX3CR1 axis may be a good molecular target for preventing PTL.

28 January 2020 in Oncology Letters
Verified
Journal Article
Open access
PDF file
TNTomoko Noguchi
Tomoko Noguchi
KSKazuko Sakai
Kazuko Sakai
NINaoyuki Iwahashi
Naoyuki Iwahashi
KMKaho Matsuda
Kaho Matsuda
HMHitomi Matsukawa
Hitomi Matsukawa
KIKazuhiko Ino
Kazuhiko Ino
Cancer Personalized Profiling by deep Sequencing (CAPP‑Seq) is a novel ultrasensitive next‑generation sequencing‑based approach that is used to detect circulating tumor DNA (ctDNA). The aim of the present study was to compare the gene mutation profiles and blood tumor mutation burden (bTMB) measured between pre‑ and post‑neoadjuvant chemotherapy (NAC), utilizing CAPP‑seq for plasma ctDNA in patients with advanced ovarian cancer. The current study included 10 patients (6 NAC‑sensitive and 4 NAC‑resistant) clinically diagnosed as having stage III or IV ovarian cancer and were administered NAC between May 2017 and February 2019. The plasma ctDNA samples were collected at pre‑ and post‑NAC, and comprehensive gene mutation analysis was performed using CAPP‑seq. In 5 out of 6 NAC‑sensitive cases, the variant allele frequency (VAF) of non‑synonymous somatic mutations decreased following NAC. In 2 out of the 4 NAC‑resistant cases, the VAF of non‑synonymous somatic mutations increased, and new somatic mutations emerged following NAC. In regard to TP53 mutation, the rate of TP53 mutation in the NAC‑resistant cases was significantly higher compared with NAC‑sensitive cases. Finally, the bTMB decreased significantly after NAC treatment in the NAC‑sensitive cases, even though there were no significant differences in the pretreatment bTMB levels between the NAC‑sensitive and NAC‑resistant cases. These results indicated that gene mutation can be profiled and monitored using liquid biopsy‑based CAPP‑Seq in patients with advanced ovarian cancer with NAC treatment, and TP53 mutation in the ctDNA and bTMB may be novel biomarkers that can be used for patient monitoring during NAC treatment.